ASCO-2016: PRE CONFERENCE INSIGHTS

The American Society of Clinical Oncology (ASCO) annual meeting happens each June in Chicago. It is one of the premier meetings each year where oncologists, scientists and advocates gather to hear the latest clinical trial data in oncology, including focused sessions on GI cancers such…

Read Full Post

FDA Approves Avastin for New Second-Line Use

For patients with metastatic colorectal cancer, the Food and Drug Administration (FDA) has approved a new use of Avastin® (bevacizumab): It can be continued as part of ‘second-line’ combination therapy, even if it was used in first-line therapy. When stage IV cancer progresses despite use…

Read Full Post

Memorial Sloan-Kettering Will Not Offer Zaltrap

Memorial Sloan-Kettering Cancer Center made a very public announcement—and explanation—today in a New York Times op-ed about why they will not offer the new drug Zaltrap® (ziv-aflibercept) to its metastatic colorectal cancer patients. The authors, all world-renowned cancer specialists at the world’s oldest cancer center, in…

Read Full Post

FDA Avastin Breast Cancer Decision Doesn't Impact Colorectal Cancer Treatment

Although FDA Commissioner Margaret Hamburg announced a final decision on November 18 to drop breast cancer from the Avastin label, metastatic colorectal cancer continues to be an approved use. The Avastin® (bevacizumab) label includes the following approved indication: Metastatic colorectal cancer, with intravenous 5-fluorouracil–based chemotherapy…

Read Full Post

FDA: Avastin Can Cause Ovarian Failure

The FDA has changed the package insert for Avastin® (bevacizumab) to include information about newly identified risks for the drug including Loss of ovarian function (ovarian failure). Bone death in the jaw (osteonecrosis). Bleeding and additional blood clots in patients who have already had a…

Read Full Post

Highlights from ASCO 2011

While there weren’t new blockbuster announcements for colorectal cancer this year at the American Society for Clinical Oncology’s (ASCO) Annual Meeting, there was plenty of focus on making what we already have work better and on choosing the patients who will benefit the most from…

Read Full Post

Leading GI Cancer Researcher Updates Patients

Last night, Dr. Edith Mitchell of Thomas Jefferson University Kimmel Cancer Center in Philadelphia, PA, updated colorectal cancer patients on the latest research and treatment news in an online webinar. Dr. Mitchell highlighted the most important news for colon and rectal cancer patients to come…

Read Full Post

AVANT Says No Avastin Benefit in Stage III Colon Cancer

A second randomized clinical trial has confirmed what the first one found — adding Avastin to standard chemotherapy does not reduce recurrences after surgery for stage III colon cancer. The AVANT trial compared standard FOLFOX chemotherapy to either FOLFOX plus Avastin® (bevacizumab) or XELOX plus…

Read Full Post

Second Avastin Trial Shows No Benefit in Early Stage Colon Cancer

Adding Avastin® (bevacizumab) to chemotherapy for early stage colon cancer didn’t reduce the risk that cancer would return. In fact, preliminary results of the AVANT trial found that chemotherapy alone worked better in preventing recurrences of stage III and high-risk stage II colon cancer, according…

Read Full Post
Page 1 of 212